Abstract Background ROS1 rearrangements (ROS1+) define a distinct molecular subset of
lung adenocarcinomas. ROS1+ tumors are known to occur more in never-smokers, but the …

ROS1 rearrangement is a predictive biomarker for response to the tyrosine kinase inhibitor,
crizotinib. We investigated the usefulness of ROS1 immunohistochemistry (IHC) for the …

11035 Background: ROS1 chromosomal rearrangement (ROS1+) was described as an
oncogenic driver in approximately 1% of non-small cell lung cancers (NSCLC). Due to the …

Background c‐ros oncogene 1 (ROS1) rearrangement presents one of the newest molecular
targets in non‐small cell lung cancer (NSCLC). ROS1 rearrangement is predominantly …

Introduction The presence of ROS proto-oncogene 1, receptor tyrosine kinase gene (ROS1)
rearrangements in lung cancers confers sensitivity to ROS kinase inhibitors, including …

Background ROS1 gene rearrangement has been reported in several types of cancers,
including non-small cell lung cancer (NSCLC). It is reported that tyrosine kinase inhibitors …

Introduction ROS1 rearrangement–positive NSCLC can be treated effectively with an
anaplastic lymphoma kinase/ROS1/mesenchymal-epithelial transition factor inhibitor such …

Background To determine the frequency and predictive impact of ROS1 rearrangements on
treatment outcomes in never-smoking patients with lung adenocarcinoma. Patients and …

The recent discovery and characterization of an oncogenic ROS1 gene fusion in a subset of
lung cancers has raised significant clinical interest because small molecule inhibitors may …

Purpose Crizotinib, a mesenchymal-epithelial transition/anaplastic lymphoma kinase/c-ros
oncogene 1 (ROS1) inhibitor, has recently been approved by the US Food and Drug …